

# Espen Molden

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/569644/espen-molden-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

80  
papers

2,068  
citations

22  
h-index

43  
g-index

94  
ext. papers

3,243  
ext. citations

4.9  
avg, IF

4.94  
L-index

#	Paper	IF	Citations
80	Effect of Valproic Acid on the Metabolic Spectrum of Clozapine in Patients With Schizophrenia.. <i>Journal of Clinical Psychopharmacology</i> , <b>2022</b> , 42, 43-50	1.7	3
79	Sex-Dependent Shared and Nonshared Genetic Architecture Across Mood and Psychotic Disorders. <i>Biological Psychiatry</i> , <b>2022</b> , 91, 102-117	7.9	11
78	The polymorphic nuclear factor NFIB regulates hepatic CYP2D6 expression and influences risperidone metabolism in psychiatric patients.. <i>Clinical Pharmacology and Therapeutics</i> , <b>2022</b> ,	6.1	2
77	Mapping genomic loci implicates genes and synaptic biology in schizophrenia.. <i>Nature</i> , <b>2022</b> ,	50.4	35
76	Association between statin use and physical performance in home-dwelling older patients receiving polypharmacy: cross-sectional study.. <i>BMC Geriatrics</i> , <b>2022</b> , 22, 242	4.1	
75	Impact of age and CYP2D6 genotype on exposure of zuclopenthixol in patients using long-acting injectable versus oral formulation-an observational study including 2044 patients. <i>European Journal of Clinical Pharmacology</i> , <b>2021</b> , 77, 215-221	2.8	2
74	Dose-Dependent Inhibition of CYP2D6 by Bupropion in Patients With Depression. <i>Journal of Clinical Psychopharmacology</i> , <b>2021</b> , 41, 281-285	1.7	1
73	Reduced Function Variants and Genotype/Phenotype Translations of CYP2D6 Intermediate Metabolizers: Implications for Personalized Drug Dosing in Psychiatry. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 650750	5.6	4
72	Evaluation of the CYP2D6 Haplotype Activity Scores Based on Metabolic Ratios of 4,700 Patients Treated With Three Different CYP2D6 Substrates. <i>Clinical Pharmacology and Therapeutics</i> , <b>2021</b> , 110, 750-758	6.1	4
71	. <i>Drug Metabolism and Disposition</i> , <b>2021</b> ,	4	8
70	Validation of a Population Pharmacokinetic Model of Vortioxetine Using Therapeutic Drug Monitoring Data. <i>Clinical Pharmacokinetics</i> , <b>2021</b> , 60, 1475-1486	6.2	1
69	Impairment of endoxifen formation in tamoxifen-treated premenopausal breast cancer patients carrying reduced-function CYP2D6 alleles. <i>British Journal of Clinical Pharmacology</i> , <b>2021</b> , 87, 1243-1252	3.8	13
68	Association of CYP2C19 and CYP2D6 Poor and Intermediate Metabolizer Status With Antidepressant and Antipsychotic Exposure: A Systematic Review and Meta-analysis. <i>JAMA Psychiatry</i> , <b>2021</b> , 78, 270-280	14.5	33
67	Rates of complete nonadherence among atypical antipsychotic drugs: A study using blood samples from 13,217 outpatients with psychotic disorders. <i>Schizophrenia Research</i> , <b>2021</b> , 228, 590-596	3.6	6
66	Impact of age and gender on paliperidone exposure in patients after administration of long-acting injectable formulations-an observational study using blood samples from 1223 patients. <i>European Journal of Clinical Pharmacology</i> , <b>2021</b> , 77, 1201-1208	2.8	0
65	European Whites May Need Lower Minimum Therapeutic Clozapine Doses Than Those Customarily Proposed. <i>Journal of Clinical Psychopharmacology</i> , <b>2021</b> , 41, 140-147	1.7	6
64	Absolute and Dose-Adjusted Serum Concentrations of Clozapine in Patients Switching vs. Maintaining Treatment: An Observational Study of 1979 Patients. <i>CNS Drugs</i> , <b>2021</b> , 35, 999-1008	6.7	0

63	Therapeutic drug monitoring of clozapine in adults with schizophrenia: a review of challenges and strategies. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2021</b> , 17, 1211-1221	5.5	3
62	Genetic Association Between Schizophrenia and Cortical Brain Surface Area and Thickness. <i>JAMA Psychiatry</i> , <b>2021</b> , 78, 1020-1030	14.5	4
61	An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels.. <i>Pharmacopsychiatry</i> , <b>2021</b> , 55,	2	11
60	Identification of a novel polymorphism associated with reduced clozapine concentration in schizophrenia patients-a genome-wide association study adjusting for smoking habits. <i>Translational Psychiatry</i> , <b>2020</b> , 10, 198	8.6	9
59	Impact of genotype-predicted CYP2D6 metabolism on clinical effects and tolerability of metoprolol in patients after myocardial infarction - a prospective observational study. <i>European Journal of Clinical Pharmacology</i> , <b>2020</b> , 76, 673-683	2.8	6
58	Prescribed Doses of CYP2D6-Metabolized Drugs and Hemodynamic Responses in Relation to CYP2D6 Genotype Among Older Patients Exposed to Polypharmacy. <i>Drugs and Aging</i> , <b>2020</b> , 37, 425-433 <sup>4.7</sup>		
57	The Influence of Combined CYP2D6 and CYP2C19 Genotypes on Venlafaxine and O-Desmethylvenlafaxine Concentrations in a Large Patient Cohort. <i>Journal of Clinical Psychopharmacology</i> , <b>2020</b> , 40, 137-144	1.7	7
56	Effect of medicines management versus standard care on readmissions in multimorbid patients: a randomised controlled trial. <i>BMJ Open</i> , <b>2020</b> , 10, e041558	3	1
55	Undetectable or subtherapeutic serum levels of antipsychotic drugs preceding switch to clozapine. <i>NPJ Schizophrenia</i> , <b>2020</b> , 6, 17	5.5	3
54	Use of Antidepressants in Older People during a 10-Year Period: An Observational Study on Prescribed Doses and Serum Levels. <i>Drugs and Aging</i> , <b>2020</b> , 37, 691-701	4.7	4
53	Impact of antipsychotic polypharmacy on nonadherence of oral antipsychotic drugs - A study based on blood sample analyses from 24,239 patients. <i>European Neuropsychopharmacology</i> , <b>2020</b> , 37, 64-69	1.2	4
52	Effect of Clinical Geriatric Assessments and Collaborative Medication Reviews by Geriatrician and Family Physician for Improving Health-Related Quality of Life in Home-Dwelling Older Patients Receiving Polypharmacy: A Cluster Randomized Clinical Trial. <i>JAMA Internal Medicine</i> , <b>2020</b> , 180, 181-189	11.5	24
51	Impact of age and CYP2D6 genetics on exposure of aripiprazole and dehydroaripiprazole in patients using long-acting injectable versus oral formulation: relevance of poor and intermediate metabolizer status. <i>European Journal of Clinical Pharmacology</i> , <b>2020</b> , 76, 41-49	2.8	6
50	Effect of Grapefruit Juice Intake on Serum Level of the Endogenous CYP3A4 Metabolite 4β-Hydroxycholesterol-an Interaction Study in Healthy Volunteers. <i>AAPS Journal</i> , <b>2019</b> , 21, 58	3.7	3
49	Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study. <i>Lancet Psychiatry</i> , <b>2019</b> , 6, 418-426	23.3	60
48	Prevalence and risk factors of drug-related hospitalizations in multimorbid patients admitted to an internal medicine ward. <i>PLoS ONE</i> , <b>2019</b> , 14, e0220071	3.7	10
47	Reduction in N-Desmethylclozapine Level Is Determined by Daily Dose But Not Serum Concentration of Valproic Acid-Indications of a Presystemic Interaction Mechanism. <i>Therapeutic Drug Monitoring</i> , <b>2019</b> , 41, 503-508	3.2	8
46	Serum Concentrations and Elimination Rates of Direct-Acting Oral Anticoagulants (DOACs) in Older Hip Fracture Patients Hospitalized for Surgery: A Pilot Study. <i>Drugs and Aging</i> , <b>2019</b> , 36, 65-71	4.7	9

45	Significantly lower CYP2D6 metabolism measured as the O/N-desmethylvenlafaxine metabolic ratio in carriers of CYP2D6*41 versus CYP2D6*9 or CYP2D6*10: a study on therapeutic drug monitoring data from 1003 genotyped Scandinavian patients. <i>British Journal of Clinical Pharmacology</i> , <b>2019</b> , 85, 194-201	3.8	18
44	Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection. <i>Nature Genetics</i> , <b>2018</b> , 50, 381-389	36.3	787
43	Comparison of CYP3A4-Inducing Capacity of Enzyme-Inducing Antiepileptic Drugs Using 4β-Hydroxycholesterol as Biomarker. <i>Therapeutic Drug Monitoring</i> , <b>2018</b> , 40, 463-468	3.2	18
42	Impact of CYP2C19 Genotype on Escitalopram Exposure and Therapeutic Failure: A Retrospective Study Based on 2,087 Patients. <i>American Journal of Psychiatry</i> , <b>2018</b> , 175, 463-470	11.9	75
41	Associations between Cytokine Levels and CYP3A4 Phenotype in Patients with Rheumatoid Arthritis. <i>Drug Metabolism and Disposition</i> , <b>2018</b> , 46, 1384-1389	4	9
40	Gjestad et al. reply to RWas 4βhydroxycholesterol ever going to be a useful marker of CYP3A4 activity? Rby Neuhoﬀ and Tucker. <i>British Journal of Clinical Pharmacology</i> , <b>2018</b> , 84, 1624-1625	3.8	2
39	Utilisation and polypharmacy aspects of antiepileptic drugs in elderly versus younger patients with epilepsy: A pharmacoepidemiological study of CNS-active drugs in Norway, 2004-2015. <i>Epilepsy Research</i> , <b>2018</b> , 139, 35-42	3	22
38	Elevated 4βhydroxycholesterol/cholesterol ratio in anorexia nervosa patients. <i>Pharmacology Research and Perspectives</i> , <b>2018</b> , 6, e00430	3.1	5
37	Age Impacts Olanzapine Exposure Differently During Use of Oral Versus Long-Acting Injectable Formulations: An Observational Study Including 8,288 Patients. <i>Journal of Clinical Psychopharmacology</i> , <b>2018</b> , 38, 570-576	1.7	12
36	The CYP3A biomarker 4βhydroxycholesterol does not improve tacrolimus dose predictions early after kidney transplantation. <i>British Journal of Clinical Pharmacology</i> , <b>2017</b> , 83, 1457-1465	3.8	15
35	4βHydroxycholesterol level significantly correlates with steady-state serum concentration of the CYP3A4 substrate quetiapine in psychiatric patients. <i>British Journal of Clinical Pharmacology</i> , <b>2017</b> , 83, 2398-2405	3.8	13
34	Bodyweight-adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance. <i>British Journal of Clinical Pharmacology</i> , <b>2017</b> , 83, 1350-1352	3.8	5
33	Correlation Between Serum Concentrations of N-Desmethylclozapine and Granulocyte Levels in Patients with Schizophrenia: A Retrospective Observational Study. <i>CNS Drugs</i> , <b>2017</b> , 31, 991-997	6.7	8
32	Individual variability in clinical effect and tolerability of opioid analgesics - Importance of drug interactions and pharmacogenetics. <i>Scandinavian Journal of Pain</i> , <b>2017</b> , 17, 193-200	1.9	22
31	Recovery of CYP3A Phenotype after Kidney Transplantation. <i>Drug Metabolism and Disposition</i> , <b>2017</b> , 45, 1260-1265	4	1
30	Combined Effect of CYP2B6 Genotype and Other Candidate Genes on a Steady-State Serum Concentration of Methadone in Opioid Maintenance Treatment. <i>Therapeutic Drug Monitoring</i> , <b>2017</b> , 39, 550-555	3.2	25
29	Cooperation between geriatricians and general practitioners for improved pharmacotherapy in home-dwelling elderly people receiving polypharmacy - the COOP Study: study protocol for a cluster randomised controlled trial. <i>Trials</i> , <b>2017</b> , 18, 158	2.8	9
28	Effect of teaching and checklist implementation on accuracy of medication history recording at hospital admission. <i>International Journal of Clinical Pharmacy</i> , <b>2016</b> , 38, 20-4	2.3	4

27	4β-hydroxycholesterol correlates with dose but not steady-state concentration of carbamazepine: indication of intestinal CYP3A in biomarker formation?. <i>British Journal of Clinical Pharmacology</i> , <b>2016</b> , 81, 269-76	3.8	23
26	Impact of Ageing on Serum Concentrations of Risperidone and Its Active Metabolite in Patients with Known CYP2D6 Genotype. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2016</b> , 119, 470-475	3.1	10
25	Risperidone and Venlafaxine Metabolic Ratios Strongly Predict a CYP2D6 Poor Metabolizing Genotype. <i>Therapeutic Drug Monitoring</i> , <b>2016</b> , 38, 127-34	3.2	24
24	Impact of genetic variability in CYP2D6, CYP3A5, and ABCB1 on serum concentrations of quetiapine and N-desalkylquetiapine in psychiatric patients. <i>Therapeutic Drug Monitoring</i> , <b>2015</b> , 37, 256-61	3.2	17
23	Therapeutic Drug Monitoring of Selective Serotonin Reuptake Inhibitors in Elderly Patients. <i>Therapeutic Drug Monitoring</i> , <b>2015</b> , 37, 546-9	3.2	9
22	Impact of age on serum concentrations of venlafaxine and escitalopram in different CYP2D6 and CYP2C19 genotype subgroups. <i>European Journal of Clinical Pharmacology</i> , <b>2014</b> , 70, 933-40	2.8	31
21	Serum concentrations of risperidone and aripiprazole in subgroups encoding CYP2D6 intermediate metabolizer phenotype. <i>Therapeutic Drug Monitoring</i> , <b>2014</b> , 36, 80-5	3.2	21
20	Severity and management of drug-drug interactions in acute geriatric patients. <i>Drugs and Aging</i> , <b>2013</b> , 30, 721-7	4.7	13
19	Influence of CYP1A1/CYP1A2 and AHR polymorphisms on systemic olanzapine exposure. <i>Pharmacogenetics and Genomics</i> , <b>2013</b> , 23, 279-85	1.9	17
18	Evaluation of organic anion-transporting polypeptide 1B1 and CYP3A4 activities in primary human hepatocytes and HepaRG cells cultured in a dynamic three-dimensional bioreactor system. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2012</b> , 343, 145-56	4.7	17
17	Serum concentrations of antidepressants in the elderly. <i>Therapeutic Drug Monitoring</i> , <b>2012</b> , 34, 25-30	3.2	28
16	Pharmacokinetic variability of quetiapine and the active metabolite N-desalkylquetiapine in psychiatric patients. <i>Therapeutic Drug Monitoring</i> , <b>2011</b> , 33, 222-6	3.2	32
15	The effect of ethinylestradiol-containing contraceptives on the serum concentration of olanzapine and N-desmethyl olanzapine. <i>British Journal of Clinical Pharmacology</i> , <b>2011</b> , 71, 611-5	3.8	12
14	OATP1B1/1B3 activity in plated primary human hepatocytes over time in culture. <i>Biochemical Pharmacology</i> , <b>2011</b> , 82, 1219-26	6	32
13	Increased frequency of CYP2C9 variant alleles and homozygous VKORC1*2B carriers in warfarin-treated patients with excessive INR response. <i>European Journal of Clinical Pharmacology</i> , <b>2010</b> , 66, 525-30	2.8	8
12	Metabolism of quetiapine by CYP3A4 and CYP3A5 in presence or absence of cytochrome B5. <i>Drug Metabolism and Disposition</i> , <b>2009</b> , 37, 254-8	4	50
11	Risk management of simvastatin or atorvastatin interactions with CYP3A4 inhibitors. <i>Drug Safety</i> , <b>2008</b> , 31, 587-96	5.1	31
10	Simvastatin-associated rhabdomyolysis after coadministration of macrolide antibiotics in two patients. <i>Pharmacotherapy</i> , <b>2007</b> , 27, 603-7	5.8	27

9	The effect of variable cigarette consumption on the interaction with clozapine and olanzapine. <i>European Journal of Clinical Pharmacology</i> , <b>2006</b> , 62, 1049-53	2.8	116
8	Celecoxib is often combined with cytochrome P450 2D6 substrates in general clinical practice. <i>Clinical Pharmacology and Therapeutics</i> , <b>2005</b> , 78, 93	6.1	2
7	Co-prescription of cytochrome P450 2D6/3A4 inhibitor-substrate pairs in clinical practice. A retrospective analysis of data from Norwegian primary pharmacies. <i>European Journal of Clinical Pharmacology</i> , <b>2005</b> , 61, 119-25	2.8	28
6	Variability in Cytochrome P450-Mediated Metabolism of Cardiovascular Drugs: Clinical Implications and Practical Attempts to Avoid Potential Problems. <i>Cardiology</i> , <b>2004</b> , 4, 55-79		6
5	High-performance liquid chromatography-mass spectrometry analysis of diltiazem and 11 of its phase I metabolites in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2003</b> , 33, 275-85	3.5	23
4	Pharmacokinetics of diltiazem and its metabolites in relation to CYP2D6 genotype. <i>Clinical Pharmacology and Therapeutics</i> , <b>2002</b> , 72, 333-42	6.1	39
3	Desacetyl-diltiazem displays severalfold higher affinity to CYP2D6 compared with CYP3A4. <i>Drug Metabolism and Disposition</i> , <b>2002</b> , 30, 1-3	4	33
2	CYP2D6 is involved in O-demethylation of diltiazem. An in vitro study with transfected human liver cells. <i>European Journal of Clinical Pharmacology</i> , <b>2000</b> , 56, 575-9	2.8	28
1	Extensive metabolism of diltiazem and P-glycoprotein-mediated efflux of desacetyl-diltiazem (M1) by rat jejunum in vitro. <i>Drug Metabolism and Disposition</i> , <b>2000</b> , 28, 107-9	4	14